Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating how well CagriSema and cagrilintide help children and adolescents aged 8 to under 18 years with excess body weight lose weight. This phase 3 study compares these new study drugs with semaglutide, a medication already prescribed for adolescents and adults, and a placebo. The trial aims to understand the efficacy, safety, and pharmacokinetics of these treatments for weight management in young people with overweight or obesity. Participants are randomly assigned to receive once weekly subcutaneous doses of either CagriSema a combination of cagrilintide and semaglutide, cagrilintide alone, semaglutide alone, or placebo in a dose escalation regimen for up to 16 weeks, followed by maintenance for a total of 52 weeks in the main study. Those who participate in the extension study will continue receiving either CagriSema or cagrilintide for up to an additional 156 weeks. Participants receiving semaglutide do not enter the extension phase. The placebo group will receive a matched placebo during the main phase and then continue on the CagriSema regimen during the extension. During the study, participants will be closely monitored through various assessments including body mass index BMI changes, body weight, fat and muscle measurements by imaging methods like MRI and DXA scans, blood tests for metabolic markers, and quality of life questionnaires. These evaluations occur at baseline, week 68, and for some measures, week 224. Safety is monitored by tracking adverse events and other health indicators. The total participation time is about 1.5 years in the main study and up to nearly 5 years if including the extension phase.
Actively Recruiting
Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.
Actively Recruiting
Researchers are studying the long-term effects of aleniglipron, taken once daily, in adults with obesity or overweight who also have weight-related health problems. This Phase 3 global, randomized, placebo-controlled, and double-blind trial aims to evaluate how well aleniglipron works, how safe it is, and how well patients tolerate it over at least 76 weeks. The study also compares aleniglipron with placebo in terms of body weight changes, blood pressure, lipid levels, and patient-reported outcomes. Participants will be randomly assigned to receive one of three doses of aleniglipron or a placebo, all taken orally once daily. Along with the medication, all participants will follow a reduced-calorie diet and increase physical activity. The treatment phase lasts at least 76 weeks, during which effects on weight and other health measures will be assessed. During the study, participants will undergo assessments of body weight, waist size, blood pressure, cholesterol, blood sugar, and quality of life measures from the start through week 76. Researchers will monitor safety and tolerability throughout the treatment period. This long-term study will help understand the impact of aleniglipron on weight management and related health factors over more than a year of treatment.
Actively Recruiting
Researchers are evaluating WIN378, an ultra-long-acting medicine, in adults with moderate to severe asthma to assess its safety, how the body processes it, and its effects on lung function and asthma control. This global Phase 2 study has two parts Part A focuses on finding the right dose of WIN378, while Part B tests the chosen doses against placebo in adults with severe uncontrolled asthma to evaluate reduction in asthma flare-ups and improvements in quality of life. Participants receive WIN378 or placebo via subcutaneous injections. Part A tests three doses to understand pharmacokinetics, safety, and efficacy, including markers of inflammation in breath and blood, lung function, and asthma control. An interim analysis selects two doses for Part B, which compares these doses against placebo over 24 weeks to assess the annualized asthma exacerbation rate, lung function improvements, asthma control, and safety. During the study, participants undergo regular assessments including lung function tests, blood and breath tests for inflammation, questionnaires on asthma symptoms and quality of life, and monitoring for adverse events. Researchers track drug levels in the body and immune responses over about 60 weeks in Part A and 24 weeks after last dose in Part B. The total participation duration extends up to nearly five years, with continuous safety and efficacy monitoring.
Actively Recruiting
Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.